Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024, in New York City. Thomas Zindrick, President, Chairman and CEO, will engage in a fireside chat with Emily Bodnar, Vice President of Equity Research and H.C. Wainwright Biotechnology Analyst, on September 11 at 12:30 p.m. ET.
The presentation will cover Genelux's clinical-stage programs, recent announcements, and upcoming milestones. A webcast of the event will be available, with an archived replay accessible for approximately 90 days on the company's IR page. Genelux will also participate in virtual one-on-one meetings during the conference, offering institutional investors the opportunity to engage directly with management.
Genelux (NASDAQ: GNLX), un'azienda immuno-oncologica in fase avanzata di sviluppo clinico, ha annunciato la sua partecipazione alla H.C. Wainwright Global Healthcare Conference che si svolgerà dal 9 all'11 settembre 2024 a New York City. Thomas Zindrick, Presidente, Chairman e CEO, parteciperà a una chiacchierata informale con Emily Bodnar, Vicepresidente della Ricerca sulle Azioni e Analista Biotech per H.C. Wainwright, l'11 settembre alle 12:30 p.m. ET.
La presentazione tratterà i programmi clinici di Genelux, gli annunci recenti e i traguardi futuri. Sarà disponibile una trasmissione in diretta dell'evento, con una registrazione archiviata accessibile per circa 90 giorni sulla pagina IR dell'azienda. Genelux parteciperà anche a incontri virtuali one-to-one durante la conferenza, offrendo agli investitori istituzionali l'opportunità di interagire direttamente con il management.
Genelux (NASDAQ: GNLX), una empresa de inmuno-oncología en etapa clínica avanzada, ha anunciado su participación en la H.C. Wainwright Global Healthcare Conference que se llevará a cabo del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York. Thomas Zindrick, Presidente, Chairman y CEO, participará en una charla informal con Emily Bodnar, Vicepresidenta de Investigación de Equidad y Analista en Biotecnología de H.C. Wainwright, el 11 de septiembre a las 12:30 p.m. ET.
La presentación abarcará los programas clínicos de Genelux, anuncios recientes y hitos futuros. Se podrá acceder a una transmisión en vivo del evento, con una repetición archivada disponible durante aproximadamente 90 días en la página de IR de la empresa. Genelux también participará en reuniones virtuales uno a uno durante la conferencia, ofreciendo a los inversores institucionales la oportunidad de interactuar directamente con la dirección.
Genelux (NASDAQ: GNLX)는 임상 단계의 면역온콜로지 회사로서, 2024년 9월 9일부터 11일까지 뉴욕시에서 열리는 H.C. Wainwright Global Healthcare Conference에 참여한다고 발표했습니다. Thomas Zindrick 회장, 사장 및 CEO는 9월 11일 오후 12시 30분 ET에 Emily Bodnar H.C. Wainwright의 주식 연구 부사장 및 생명공학 애널리스트와 불꽃놀이 대화를 나눌 예정입니다.
발표에서는 Genelux의 임상 단계 프로그램, 최근 발표된 내용 및 다가오는 주요 일정이 다뤄질 것입니다. 이벤트의 웹캐스트가 제공되며, 회사의 IR 페이지에서 약 90일 동안 볼 수 있는 아카이브 재생이 가능합니다. Genelux는 또한 컨퍼런스 동안 가상 일대일 미팅에도 참여하여 기관 투자자들이 경영진과 직접 소통할 기회를 제공합니다.
Genelux (NASDAQ: GNLX), une entreprise d'immuno-oncologie en phase clinique avancée, a annoncé sa participation à la H.C. Wainwright Global Healthcare Conference qui se déroulera du 9 au 11 septembre 2024 à New York. Thomas Zindrick, Président, Président du Conseil et CEO, participera à une discussion informelle avec Emily Bodnar, Vice-présidente de la recherche en actions et analyste en biotechnologie chez H.C. Wainwright, le 11 septembre à 12h30 ET.
La présentation couvrira les programmes cliniques de Genelux, les annonces récentes et les prochaines étapes importantes. Un webinaire de l'événement sera disponible, avec une rediffusion archivée accessible pendant environ 90 jours sur la page IR de l'entreprise. Genelux participera également à des réunions virtuelles en tête-à-tête pendant la conférence, offrant aux investisseurs institutionnels l'opportunité d'interagir directement avec la direction.
Genelux (NASDAQ: GNLX), ein Unternehmen im fortgeschrittenen klinischen Stadium der Immunonkologie, hat seine Teilnahme an der H.C. Wainwright Global Healthcare Conference angekündigt, die vom 9. bis 11. September 2024 in New York City stattfindet. Thomas Zindrick, Präsident, Vorsitzender und CEO, wird am 11. September um 12:30 Uhr ET ein Fireside Chat mit Emily Bodnar, Vizepräsidentin der Aktienforschung und Biotech-Analystin bei H.C. Wainwright, führen.
Die Präsentation wird die klinischen Programme von Genelux, aktuelle Ankündigungen und bevorstehende Meilensteine abdecken. Ein Webcast der Veranstaltung wird verfügbar sein, mit einer archivierten Wiedergabe, die etwa 90 Tage auf der IR-Seite des Unternehmens zugänglich ist. Genelux wird auch an virtuellen Einzelgesprächen während der Konferenz teilnehmen und institutionellen Anlegern die Möglichkeit bieten, direkt mit dem Management in Kontakt zu treten.
- None.
- None.
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York.
The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend virtual one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference virtually or contact genelux@allelecomms.com.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) presenting at the H.C. Wainwright Global Healthcare Conference?
Who will be representing Genelux (GNLX) at the H.C. Wainwright conference?
What topics will Genelux (GNLX) discuss at the H.C. Wainwright conference?
How can investors access Genelux 's (GNLX) presentation at the H.C. Wainwright conference?
Will Genelux (GNLX) be available for one-on-one meetings during the H.C. Wainwright conference?
